Navigation Links
ThermoGenesis Names Tiffany Olson to Board of Directors
Date:8/6/2008

Former Head of Roche Diagnostics, North America, Has 25 Years of Life

Sciences Industry Experience

RANCHO CORDOVA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products that process and store adult stem cells, said today that Tiffany P. Olson, formerly President and Chief Executive Officer, Roche Diagnostics Corporation, North America, has been named to the Company's Board of Directors. Her appointment brings the Company's number of directors to six.

Olson, who has more than 25 years of healthcare industry experience, led the over one billion dollar operation for Roche Diagnostics Corporation for three years. Roche Diagnostics is a world-leader in in-vitro diagnostics and specializes in products and services for the molecular, chemistry, immunology, point-of care and life sciences markets. She joined Roche in 1997 and her positions also included Global Market Development and Quality, Vice President, Molecular Diagnostics, United States and other senior positions.

"Tiffany's appointment is emblematic of our initiative to elevate both the Board of Directors and management team at ThermoGenesis. Her extensive experience in key areas of the healthcare industry will provide us invaluable insight as we pursue our growth strategies in that market," said Dr. William Osgood, Chief Executive Officer of ThermoGenesis.

"This is an exciting time to be associated with ThermoGenesis. It is building upon its already strong position in regenerative medicine through developments such as the recent FDA authorization of its MarrowXpress(TM) and I look forward to working with the management team," Olson commented.

Olson holds a B.S. in Business from the University of Minnesota School of Management and an MBA from the University of St. Thomas in St. Paul, Minnesota.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.

-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of automated devices that includes the AXP and the MarrowXpress(TM) and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow. ThermoGenesis sells the MarrowXpress directly to global customers.

-- The CryoSeal(R) FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The CE-Marked TPD is currently being marketed in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and independent distributors.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Investor Relations

916-858-5107, or

ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Human ... report to their offering. ... This report analyzes the Global market for Human Embryonic ... are provided for the period 2014 through 2022. Market data and ... The report profiles 25 companies including many key and niche players ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):